Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes

NCT01973231 on ClinicalTrials.gov · last registry update 2017-02-09

An unusually large phase 4: 404 participants, more than double the 75 typical for the stage. The sponsor logged completion for November 2014. Primary outcome, as filed: Change in Glycosylated Haemoglobin (HbA1c) From Baseline. liraglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 404
Started: 2013-10
Primary completion: 2014-11 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Glycosylated Haemoglobin (HbA1c) From Baseline

Conditions studied

Diabetes · Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.